Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.31 |
| ▸ | BMPR1A | P36894 | 2/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.31 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.31 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL722905 | 0.84 | PDE4B (0.37) | PDE4B | |
| SCHEMBL20007553 | 0.79 | ADRA2A (0.35) | — | |
| SCHEMBL21001814 | 0.76 | BMPR1B (0.42) | PDE4BBMPR1BBMPR1ATGFBR1ACVRL1 | |
| SCHEMBL30404865 | 0.76 | BMPR1B (0.42) | PDE4BBMPR1BBMPR1ATGFBR1ACVRL1 | |
| SCHEMBL19588445 | 0.75 | — | — | |
| SCHEMBL18403229 | 0.75 | — | — | |
| SCHEMBL25570146 | 0.71 | — | — | |
| SCHEMBL8137963 | 0.69 | HSD17B10 (0.41) | PDE4BBMPR1BBMPR1ATGFBR1ACVRL1 | |
| SCHEMBL15207117 | 0.69 | KMT2A (0.52) | KDM4EHSD17B10 | |
| SCHEMBL18673407 | 0.68 | HSD17B10 (0.31) | HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10028942-B2 | 3-substituted pyrazoles and uses thereof | GENENTECH, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-9814704-B2 | Substituted pyrrolo[2,3-b]pyridines as MLK inhibitors | THE UNIVERSITY OF ROCHESTER (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170087137-A1 | 3-SUBSTITUTED PYRAZOLES AND USES THEREOF | GENENTECH, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-9550777-B2 | 3-substituted pyrazoles and use as DLK inhibitors | GENENTECH, INC. (US) | 2017-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170087137-A1 | 3-SUBSTITUTED PYRAZOLES AND USES THEREOF | PDXK, NLK, PDK3 | PDE4B 607/4885BMPR1B 3853/4885BMPR1A 4194/4885 |
| US-10028942-B2 | 3-substituted pyrazoles and uses thereof | PDXK, NLK, PDK3 | PDE4B 607/4885BMPR1B 3853/4885BMPR1A 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.